Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients

Journal of Clinical Oncology

Volumn 18, Issue 6, 2000, Pages 1173-1180

  Motzer, Robert J ^a   Mazumdar, Madhu ^a   Sheinfeld, Joel ^a   Bajorin, Dean F ^a   Macapinlac, Homer A ^a   Bains, Manjit ^a   Reich, Lilian ^a   Flombaum, Carlos ^a   Mariani, Tania ^a   Tong, William P ^a   Bosl, George J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DOSE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; FEVER; GERM CELL TUMOR; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034018301     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.6.1173     Document Type: Article

References (31)

1. Bosl GJ, Motzer RJ: Testicular germ-cell cancer. N Engl J Med 337:242-253, 1997
2. McCaffrey JA, Mazumdar M, Bajorin DF, et al: Ifosfamide-and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 15:2559-2563, 1997
3. Loehrer PJ, Gonin R, Nichols CR, et al: Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J Clin Oncol 16:2500-2504, 1998
4. Motzer RJ, Mazumdar M, Bosl GJ, et al: High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity. J Clin Oncol 14:1098-1105, 1996
5. Linkesch W, Greinix HT, Hocker P, et al: Longterm follow up of phase I/II trial of ultra-high carboplatin, VP16, cyclophosphamide with ABMT in refractory or relapsed NSGCT. Proc Am Soc Clin Oncol 12:232, 1993 (abstr 717)
6. Broun ER, Nichols CR, Kneebone P, et al: Long-term outcome of patients with relapsed and refractory germ cell tumors treated with high-dose chemotherapy and autologous bone marrow rescue. Ann Intern Med 117:124-128, 1992
7. Motzer RJ, Geller NL, Tan CC, et al: Salvage chemotherapy for patients with germ cell tumors: The Memorial Sloan-Kettering Cancer Center experience (1979-1989). Cancer 67:1305-1310, 1991
8. Motzer RJ, Green GA, McCaffrey JA, et al: Paclitaxel (T), ifosfamide (I), and cisplatin (P) as first-line salvage therapy for relapsed germ cell tumor (GCT) patients with favorable prognostic features. Proc Am Soc Clin Oncol 17:322a, 1998 (abstr 1241)
9. Motzer RJ: Selecting patients with cisplatin-resistant germ cell tumors for high-dose chemotherapy. J Clin Oncol 14:2625-2626, 1997
10. Norton L, Simon R: The Norton-Simon hypothesis revisited. Cancer Treat Rep 70:163-169, 1986
11. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
12. Fawdry RM, Gruenewald SM: Three-hour volume of distribution method: An accurate simplified method of glomerular filtration rate measurement. J Nucl Med 28:510-513, 1987
13. Egorin MJ, Forrest A, Belani CP, et al: A limited sampling strategy for cyclophosphamide pharmacokinetics. Cancer Res 49:3129-3133, 1989
14. Motzer RJ, Gulati SC, Tong WP, et al: Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Cancer Res 53:3730-3735, 1993
15. 2 divided over three consecutive days. Br J Cancer 61:460-464, 1990
16. Tallarida RJ, Murray RB: Manual of Pharmacologic Calculations With Computer Programs. New York, NY, Springer-Verlag, 1990
17. Bokemeyer C, Gerl A, Schoffski P, et al: Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17:512-516, 1999
18. Rossignol B, Rossingnol D, Petitclerc C: Improvement of creatinine measurement of RA-1000. Clin Biochem 17:203-204, 1984
19. Cockgroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976
20. Jelliffe RW: Creatinine clearance: Bedside estimate. Ann Intern Med 79:604-605, 1973 (letter)
21. NCCN Proceedings: NCCN practice guidelines for testicular cancer. Oncology 11:417-462, 1998
22. Motzer RJ, Bajorin DF, Schwartz LH, et al: Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J Clin Oncol 12:2277-2283, 1994
23. Wheeler BM, Loehrer PJ, Williams SD, et al: Ifosfamide in refractory male germ cell tumors. J Clin Oncol 4:28-34, 1986
24. Motzer RJ, Chou TC, Schwartz L, et al: Paclitaxel in germ cell cancer. Semin Oncol 22:12-15, 1995
25. Ringel I, Horwitz SB: Paclitaxel affects microtubule dynamics and apoptosis. Adv Oncol 15:11-17, 1999
26. Houldsworth J, Xiao H, Murty VVV, et al: Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. Oncogene 16:2345-2349, 1999
27. Motzer RJ, Bosl GJ: High-dose chemotherapy for resistant germ cell tumors: Recent advances and future directions. J Natl Cancer Inst 84:1703-1709, 1992
28. Russell CD, Rischoff PG, Rowell KL, et al: Quality control of Tc-99m DTPA for measurement of glomerular filtration: Concise communication. J Nucl Med 24:722-727, 1983
29. Carlsen JE, Moller ML, Lund JO, et al: Comparison of tour commercial Tc-99m(Sn)DTPA preparations used for the measurement of glomerular filtration rate: Concise communication. J Nucl Med 21:126-129, 1980
30. Sorenson BT, Stromgren A, Jakobsen P, et al: Renal handling of carboplatin. Cancer Chemother Pharmacol 30:317-320, 1992
31. Reece PA, Stafford I, Russell J, et al: Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II). Cancer Chemother Pharmacol 15:295-299, 1985